Zacks Research Has Optimistic Outlook of CLB FY2026 Earnings

Core Laboratories Inc. (NYSE:CLB) – Research analysts at Zacks Research increased their FY2026 earnings per share (EPS) estimates for Core Laboratories in a note issued to investors on Wednesday, August 19th. Zacks Research analyst Team now anticipates that the oil and gas company will post earnings of $0.62 per share for the year, up from their previous forecast of $0.57. The consensus estimate for Core Laboratories’ current full-year earnings is $0.53 per share. Zacks Research also issued estimates for Core Laboratories’ Q3 2027 earnings at $0.16 EPS, FY2027 earnings at $0.77 EPS and Q2 2028 earnings at $0.31 EPS.

A number of other analysts also recently issued reports on CLB. Wall Street Zen raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Johnson Rice raised shares of Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a report on Thursday, August 13th. Finally, Weiss Ratings upgraded shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Core Laboratories Price Performance

Shares of NYSE:CLB opened at $12.67 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.55 and a current ratio of 2.12. The firm has a market cap of $581.21 million, a price-to-earnings ratio of 22.62, a price-to-earnings-growth ratio of 3.02 and a beta of 1.03. The business has a 50-day simple moving average of $11.55 and a two-hundred day simple moving average of $14.52. Core Laboratories has a fifty-two week low of $9.79 and a fifty-two week high of $20.36.

Core Laboratories (NYSE:CLB) last released its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.The company had revenue of $124.61 million for the quarter, compared to analysts’ expectations of $126.26 million. During the same period last year, the firm posted $0.19 earnings per share. Core Laboratories’s revenue was down 4.3% compared to the same quarter last year. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS.

Institutional Trading of Core Laboratories

Hedge funds have recently bought and sold shares of the stock. CWM LLC increased its position in Core Laboratories by 36.1% in the fourth quarter. CWM LLC now owns 2,516 shares of the oil and gas company’s stock worth $40,000 after buying an additional 668 shares in the last quarter. Platinum Investment Management Ltd. raised its stake in shares of Core Laboratories by 3.9% in the third quarter. Platinum Investment Management Ltd. now owns 23,758 shares of the oil and gas company’s stock worth $294,000 after buying an additional 889 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Core Laboratories by 6.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company’s stock valued at $207,000 after buying an additional 1,040 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Core Laboratories by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company’s stock valued at $418,000 after buying an additional 1,170 shares in the last quarter. Finally, Quarry LP grew its stake in shares of Core Laboratories by 118.1% during the 3rd quarter. Quarry LP now owns 2,953 shares of the oil and gas company’s stock valued at $36,000 after acquiring an additional 1,599 shares during the period. Institutional investors own 97.81% of the company’s stock.

Insider Activity at Core Laboratories

In related news, CEO Lawrence Bruno acquired 5,000 shares of Core Laboratories stock in a transaction dated Friday, July 31st. The stock was purchased at an average cost of $10.78 per share, for a total transaction of $53,900.00. Following the purchase, the chief executive officer directly owned 262,438 shares of the company’s stock, valued at approximately $2,829,081.64. This trade represents a 1.94% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 1.26% of the stock is owned by company insiders.

Core Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Monday, August 10th will be paid a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, August 10th. Core Laboratories’s dividend payout ratio is 7.14%.

About Core Laboratories

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.